Structural Insights into a Wildtype Domain of the Oncoprotein E6 and Its Interaction with a PDZ Domain

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Mischo, André ^a   Ohlenschläger, Oliver ^a   Hortschansky, Peter ^b   Ramachandran, Ramadurai ^a   Görlach, Matthias ^a  

^a FRITZ LIPMANN INSTITUTE   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; DLG1 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; ZINC;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL POLARITY; CONTROLLED STUDY; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PDZ DOMAIN; PROTEIN DOMAIN; PROTEIN FOLDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; TEMPERATURE SENSITIVITY; WILD TYPE; ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PAPILLOMAVIRUS INFECTION; PROTEIN CONFORMATION; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; HUMANS; MEMBRANE PROTEINS; MODELS, MOLECULAR; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PDZ DOMAINS; PROTEIN BINDING; PROTEIN CONFORMATION; ZINC;

EID: 84876974082     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062584     Document Type: Article

References (91)

1. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
2. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Gravitt PE, (2011) The known unknowns of HPV natural history. J Clin Invest 121: 4593-4599.
4. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632.
5. Durst M, Dzarlieva-Petrusevska RT, Boukamp P, Fusenig NE, Gissmann L, (1987) Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1: 251-256.
6. Hudson JB, Bedell MA, McCance DJ, Laiminis LA, (1990) Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64: 519-526.
7. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R, (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63: 4417-4421.
8. Magaldi TG, Almstead LL, Bellone S, Prevatt EG, Santin AD, et al. (2012) Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation. Virology 422: 114-124.
9. Hwang ES, Riese DJ, 2nd, Settleman J, Nilson LA, Honig J, et al (1993) Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virol 67: 3720-3729.
10. Dowhanick JJ, McBride AA, Howley PM, (1995) Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 69: 7791-7799.
11. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F, (1997) Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 16: 504-514.
12. Jiang M, Milner J, (2002) Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21: 6041-6048.
13. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, et al. (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22: 5938-5945.
14. Parish JL, Kowalczyk A, Chen H-T, Roeder GE, Sessions R, et al. (2006) E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. J Virol 80: 4580-4590.
15. Gaiffe E, Pretet J-L, Launay S, Jacquin E, Saunier M, et al. (2012) Apoptotic HPV positive cancer cells exhibit transforming properties. PLoS One 7.
16. Pett M, Coleman N, (2007) Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 212: 356-367.
17. Moody CA, Laimins LA, (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-560.
18. Tungteakkhun SS, Duerksen-Hughes PJ, (2008) Cellular binding partners of the human papillomavirus E6 protein. Arch Virol 153: 397-408.
19. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
20. Werness BA, Levine AJ, Howley PM, (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79.
21. Huibregtse JM, Scheffner M, Howley PM, (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10: 4129-4135.
22. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM, (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
23. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
24. Massimi P, Shai A, Lambert P, Banks L, (2008) HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene 27: 1800-1804.
25. Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, et al. (2007) Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene 26: 4059-4070.
26. Fu L, Van Doorslaer K, Chen Z, Ristriani T, Masson M, et al. (2010) Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One 5.
27. Mesplede T, Gagnon D, Bergeron-Labrecque F, Azar I, Senechal H, et al. (2012) p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol 86: 94-9107.
28. Howie HL, Katzenellenbogen RA, Galloway DA, (2009) Papillomavirus E6 proteins. Virology 384: 324-334.
29. Liu X, Dakic A, Zhang Y, Dai Y, Chen R, et al. (2009) HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc Natl Acad Sci U S A 106: 18780-18785.
30. Van Doorslaer K, Burk RD, (2012) Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology 433: 216-219.
31. Thomas M, Narayan N, Pim D, Tomaic V, Massimi P, et al. (2008) Human papillomaviruses, cervical cancer and cell polarity. Oncogene 27: 7018-7030.
32. Muench P, Hiller T, Probst S, Florea A-M, Stubenrauch F, et al. (2009) Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. Virology 387: 380-387.
33. Lee C, Laimins LA, (2004) Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J Virol 78: 12366-12377.
34. Shai A, Brake T, Somoza C, Lambert PF, (2007) The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 67: 1626-1635.
35. Javier RT, (2008) Cell polarity proteins: common targets for tumorigenic human viruses. Oncogene 27: 7031-7046.
36. Javier RT, Rice AP, (2011) Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses. J Virol 85: 11544-11556.
37. Prehaud C, Wolff N, Terrien E, Lafage M, Megret F, et al. (2010) Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein. Sci Signal 3.
38. Gardiol D, Kuhne C, Glaunsinger B, Lee SS, Javier R, et al. (1999) Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18: 5487-5496.
39. Bryant DM, Mostov KE, (2008) From cells to organs: building polarized tissue. Nat Rev Mol Cell Biol 9: 887-901.
40. Laprise P, Viel A, Rivard N, (2004) Human homolog of disc-large is required for adherens junction assembly and differentiation of human intestinal epithelial cells. J Biol Chem 279: 10157-10166.
41. Roberts S, Delury C, Marsh E, (2012) The PDZ protein discs-large (DLG): the 'Jekyll and Hyde' of the epithelial polarity proteins. FEBS J 279: 3549-3558.
42. Facciuto F, Cavatorta AL, Valdano MB, Marziali F, Gardiol D, (2012) Differential expression of PDZ domain-containing proteins in human diseases- challenging topics and novel issues. FEBS J 279: 3538-3548.
43. Ishidate T, Matsumine A, Toyoshima K, Akiyama T, (2000) The APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase. Oncogene 19: 365-372.
44. Massimi P, Zori P, Roberts S, Banks L (2012) Differential regulation of cell-cell contact, invasion and anoikis by hScrib and hDlg in keratinocytes. PLoS One 7.
45. Krishna Subbaiah V, Massimi P, Boon SS, Myers MP, Sharek L, et al. (2012) The invasive capacity of HPV transformed cells requires the hDlg-dependent enhancement of SGEF/RhoG activity. PLoS Pathog 8: e1002543.
46. Barbosa MS, Lowy DR, Schiller JT, (1989) Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol 63: 1404-1407.
47. Nomine Y, Ristriani T, Laurent C, Lefevre JF, Weiss E, et al. (2001) Formation of soluble inclusion bodies by hpv e6 oncoprotein fused to maltose-binding protein. Protein Expr Purif 23: 22-32.
48. Liu Y, Cherry JJ, Dineen JV, Androphy EJ, Baleja JD, (2009) Determinants of stability for the E6 protein of papillomavirus type 16. J Mol Biol 386: 1123-1137.
49. Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, et al. (2006) Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21: 665-678.
50. Zanier K, ould M'hamed ould Sidi A, Boulade-Ladame C, Rybin V, Chappelle A, et al. (2012) Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 20: 604-617.
51. Ristriani T, Fournane S, Orfanoudakis G, Trave G, Masson M, (2009) A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene 28: 762-772.
52. Zhang Y, Dasgupta J, Ma RZ, Banks L, Thomas M, et al. (2007) Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J Virol 81: 3618-3626.
53. Liu Y, Henry GD, Hegde RS, Baleja JD, (2007) Solution structure of the hDlg/SAP97 PDZ2 domain and its mechanism of interaction with HPV-18 papillomavirus E6 protein. Biochemistry 46: 10864-10874.
54. Nomine Y, Charbonnier S, Miguet L, Potier N, Van Dorsselaer A, et al. (2005) 1H and 15N resonance assignment, secondary structure and dynamic behaviour of the C-terminal domain of human papillomavirus oncoprotein E6. J Biomol NMR 31: 129-141.
55. Herrmann T, Guntert P, Wuthrich K, (2002) Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. J Mol Biol 319: 209-227.
56. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
57. Pople JA, (1956) Protein Magnetic Resonance of Hydrocarbons. J Chem Phys 24: 1111.
58. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, et al. (1997) Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 94: 11612-11616.
59. Mischo A, Ohlenschlager O, Guhrs K-H, Gorlach M, (2012) Recombinant production of isotope-labeled peptides and spontaneous cyclization of amino-terminal glutamine into pyroglutamic acid. Chembiochem 13: 1421-1423.
60. Mischo A, Ohlenschlager O, Ramachandran R, Gorlach M (2012) NMR assignment of a PDZ domain in complex with a HPV51 E6 derived N-terminally pyroglutamic acid modified peptide. Biomol NMR Assign.
61. Luck K, Charbonnier S, Trave G, (2012) The emerging contribution of sequence context to the specificity of protein interactions mediated by PDZ domains. FEBS Lett 586: 2648-2661.
62. International Agency for Research on Cancer (2012) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans- Vol 100B Biological Agents. WHO Press, Geneva.
63. Hiller T, Poppelreuther S, Stubenrauch F, Iftner T, (2006) Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 15: 1262-1267.
64. Nicolaides L, Davy C, Raj K, Kranjec C, Banks L, et al. (2011) Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology 414: 137-145.
65. Tomaic V, Pim D, Banks L, (2009) The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 393: 7-10.
66. Ansari T, Brimer N, Vande Pol SB, (2012) Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53. J Virol 86: 11386-11391.
67. Turoverov KK, Kuznetsova IM, Uversky VN, (2010) The protein kingdom extended: ordered and intrinsically disordered proteins, their folding, supramolecular complex formation, and aggregation. Prog Biophys Mol Biol 102: 73-84.
68. Ball LJ, Kuhne R, Schneider-Mergener J, Oschkinat H, (2005) Recognition of proline-rich motifs by protein-protein-interaction domains. Angew Chem Int Ed Engl 44: 2852-2869.
69. Freund C, Schmalz HG, Sticht J, Kuhne R (2008) Proline-rich sequence recognition domains (PRD): ligands, function and inhibition. Handb Exp Pharmacol: 407-429.
70. Neveu G, Cassonnet P, Vidalain P-O, Rolloy C, Mendoza J, et al. (2012) Comparative analysis of virus-host interactomes with a mammalian high-throughput protein complementation assay based on Gaussia princeps luciferase. Methods 58: 349-359.
71. White EA, Kramer RE, Tan MJA, Hayes SD, Harper JW, et al. (2012) Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J Virol 86: 13174-13186.
72. Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, et al. (1999) Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 73: 7297-7307.
73. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, et al. (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451-11460.
74. Lee C, Wooldridge TR, Laimins LA, (2007) Analysis of the roles of E6 binding to E6TP1 and nuclear localization in the human papillomavirus type 31 life cycle. Virology 358: 201-210.
75. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, et al. (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202: 1789-1799.
76. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, et al. (2005) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164.
77. Song S, Liem A, Miller JA, Lambert PF, (2000) Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 267: 141-150.
78. Beaudenon S, Huibregtse JM (2008) HPV E6, E6AP and cervical cancer. BMC Biochem 9 Suppl 1.
79. Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, et al. (2013) Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science 339: 694-698.
80. Songyang Z, Fanning AS, Fu C, Xu J, Marfatia SM, et al. (1997) Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 275: 73-77.
81. Charbonnier S, Nomine Y, Ramirez J, Luck K, Chapelle A, et al. (2011) The structural and dynamic response of MAGI-1 PDZ1 with noncanonical domain boundaries to the binding of human papillomavirus E6. J Mol Biol 406: 745-763.
82. Wiedemann U, Boisguerin P, Leben R, Leitner D, Krause G, et al. (2004) Quantification of PDZ domain specificity, prediction of ligand affinity and rational design of super-binding peptides. J Mol Biol 343: 703-718.
83. Zhang Z, Li H, Chen L, Lu X, Zhang J, et al. (2011) Molecular basis for the recognition of adenomatous polyposis coli by the Discs Large 1 protein. PLoS One 6.
84. Gianni S, Haq SR, Montemiglio LC, Jurgens MC, Engstrom Ö, et al. (2011) Sequence-specific long range networks in PSD-95/discs large/ZO-1 (PDZ) domains tune their binding selectivity. J Biol Chem 286: 27167-27175.
85. McLaughlin RN, Poelwijk FJ, Raman A, Gosal WS, Ranganathan R, (2012) The spatial architecture of protein function and adaptation. Nature 491: 138-142.
86. McCann JJ, Zheng L, Chiantia S, Bowen ME, (2011) Domain orientation in the N-Terminal PDZ tandem from PSD-95 is maintained in the full-length protein. Structure 19: 810-820.
87. Lue RA, Brandin E, Chan EP, Branton D, (1996) Two independent domains of hDlg are sufficient for subcellular targeting: the PDZ1-2 conformational unit and an alternatively spliced domain. J Cell Biol 135: 1125-1137.
88. Bohm G, Muhr R, Jaenicke R, (1992) Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng 5: 191-195.
89. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947-2948.
90. Clamp M, Cuff J, Searle SM, Barton GJ, (2004) The Jalview Java alignment editor. Bioinformatics 20: 426-427.
91. Livingstone CD, Barton GJ, (1993) Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation. Comput Appl Biosci 9: 745-756.